|Bid||0.00 x 1400|
|Ask||0.00 x 1300|
|Day's Range||78.66 - 85.50|
|52 Week Range||71.42 - 163.43|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 29, 2020 - May 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||139.74|
bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2019.
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences:
Just months after its first product was approved by the FDA, Cambridge’s Acceleron Pharma is closer to executing a one-two punch after announcing new clinical trial data this week.
bluebird bio, Inc. (Nasdaq: BLUE) announced the launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene), a one-time gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not have a β0/β0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. This is the first time ZYNTEGLO is commercially available.
The Biotech sector came back to life towards the end of 2019. The Nasdaq Biotechnology Index jumped up 20% between October and December, beating the S&P 500’s 9% increase. The surge, according to some analysts, is set to continue into 2020.Washington’s lack of attention to drug pricing or Medicare for All, due to present focus on trade talks and the impeachment process, along with the J.P. Morgan Healthcare Conference between Jan. 13-16, which usually generates investor interest, are both seen as reasons to be bullish. Furthermore, according to Jared Holz, a sector strategist at Jefferies, the beginning of the year is a likely period for mergers and acquisitions.“We continue to think there is much more consolidation on the horizon given the pipeline needs across large cap bio-pharma,” said Holz.This leads us to think now is a good time for bargain hunting in the Healthcare sector. So, we dug into TipRanks’ Stock Screener to find three biotech stocks that have yet to catch up with the uptick in the sector’s fortunes, but which according to the analysts, are ready to make some upward movement in 2020. Let check out the data.bluebird bio (BLUE)No one is doubting the fact that gene therapy company bluebird bio has had a rough going. We’re talking about a 50% fall in the past two years. However, Oppenheimer analyst Mark Breidenbach believes that the drop presents investors with a buying opportunity.bluebird recently presented at the annual American Society of Hematology (ASH) conference and Breidenbach was there to get the lowdown. The 4-star analyst is forecasting "blue skies” following Bluebird’s presentation.bluebird has one product approved for patients in the EU; Zynteglo, the first gene therapy approved for transfusion-dependent β-thalassemia (TDT). Breidenbach expects “Zynteglo sales in Europe to slowly begin ramping in 2020.” Bluebird plans to initiate a rolling BLA (Biological License Application) for the treatment in the US by the end of the year.Furthermore, the company has several drugs in the pipeline, of which data presented from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin gene therapy for sickle cell disease (SCD), was a highlight for the analyst.“At ASH, bluebird showcased tangible signs of progress across its hemoglobinopathy pipeline, with especially impressive results in sickle cell anemia (SCA) [...] Nine treated patients with ≥6 months follow-up showed sustained hematological improvements and a 99% reduction in serious symptoms including VOC and ACS episodes,” said Breidenbach.A further catalyst for Breidenbach is bluebird’s partnership with Bristol-Myers Squibb. The two are collaborating on a therapy candidate for patients with relapsed and refractory multiple myeloma, and positive top-line results from KarMMa, a Phase 2 study of idecabtagene vicleucel (ide-cel; bb2121) met its primary endpoint and key secondary endpoint.Breidenbach noted, “We expect pivotal data from KarMMa to support FDA approval of ide-cel by late 2020, and we believe new data from competing products could help calibrate expectations for its commercial potential."As a result, Breidenbach upgraded his rating on BLUE from Perform to Outperform, alongside a price target of $135, implying upside potential of over 50%. (To watch Breidenbach’s track record, click here)On the Street, bluebird currently has 8 Buys and 5 Hold ratings, which coalesce into a Moderate Buy consensus rating. The average price target comes in at $118.67, and represents possible upside of 36%. (See BLUE stock analysis on TipRanks)Aridis Pharmaceuticals (ARDS)Another company which struggled in 2019, is fellow micro-cap Aridis Pharmaceuticals. The biotech saw out the year with its share price down by 60%.However, H.C. Wainwright analyst Vernon Bernardino believes now is the right time for investors to hop onboard. The analyst initiated coverage on Aridis shares with a Buy rating, and set a price target of $7, implying upside potential of 57%. (To watch Bernardino’s track record, click here).So, what has piqued the analyst’s interest, then? Bernardino believes Aridis has “product candidates that present novel targets and mechanisms of action” and a clinical strategy which “is designed to achieve superiority and maximize the probability of adoption of Aridis’ fully human mAbs as first-line anti-bacterial therapies.” The analyst added, "We expect Aridis’ mAb anti-bacterial candidates to differentiate themselves through their potential to be active against antibiotic resistant strains of urgent threat bacteria.”Aridis has several therapies in the pipeline. Its most advanced candidate is AR-301, currently in a Phase 3 trial for hospital-acquired pneumonia (HAP) infection and ventilator-associated pneumonia (VAP) infection bought on by the Gram-positive bacteria, Staphylococcus aureus (S. aureus). Bernardino thinks the drug has potential for regulatory approval by 2022 and projects AR-301 could reach annual sales of approximately $700 million by 2030.Bernardino further expounded, “We believe the potential for results from the ongoing Phase 3 trial with AR-301 as adjunct therapy in patients with hospital acquired and ventilator-associated pneumonia to be a positive catalyst in early 2020 is under-appreciated.”Similarly, other Wall Street analysts like what they’re seeing. With 3 Buy ratings received in the last three months, the stock earns a ‘Strong Buy’ Street consensus. At an $18 average price target, analysts see 270% upside potential in store for Aridis. (See Aridis price targets and analyst ratings on TipRanks)Ocugen Inc (OCGN)It’s been a miserable 2019 for investors in clinical-stage biopharmaceutical company Ocugen, which saw its stock price cut nearly 90%. The low value, though, could also present opportunity, at least according to H.C. Wainwright analyst Swayampakula Ramakanth.Ramakanth initiated coverage on Ocugen with a Buy rating and set a price target of $1.25. Should the target be met, investors will see a solid 140% gains over the next 12 months. (To watch Ramakanth’s track record, click here)Ocugen’s lead candidate is OCU300, a treatment for ocular graftversus-host disease (oGVHD), a condition which can cause damage to the ocular surface and tear-producing glands and has no approved therapy. The drug is currently in a Phase 3 trial and topline results are expected in 2H20. According to estimates, there are 63,000 oGVHD patients in the US, a figure expected to grow to 140,000 by 2030.Ramakanth noted, “Given the promising data generated so far, we believe that OCU300 Phase 3 study is likely to report a positive readout, which could be a major catalyst. Additionally, OCU300 is the first and only product candidate that has received Orphan Drug Designation (ODD) from the FDA for oGVHD. We currently project OCU300 risk-adjusted revenues to reach $141M by 2030, growing from $5M in 2021.”There is little action on the Street heading Ocugen’s way right now, with only one other analyst chiming in with a view on the micro-cap’s prospects. An additional Buy rating means Ocugen qualifies as a Moderate Buy. The average price target, though, is $1.63, and implies massive upside potential of 213%. (See Ocugen price targets and analyst ratings on TipRanks)
Nick Leschly has been the CEO of bluebird bio, Inc. (NASDAQ:BLUE) since 2010. This report will, first, examine the CEO...
A handful of sickle cell disease treatments and CAR-T therapies that treat cancer have been approved by the Food and Drug Administration in recent years, but a new crop of investigational therapies that would grow those markets is exciting investors.
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 750 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of September […]
Bluebird bio is set to start earning money from drug sales next year, and SVB Leerink analyst Mani Foroohar is increasing his price target on the stock.
bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.
Stocks slipped slightly on Monday as investors work off some of Friday's jobs report rally and as trade-war headlines continue to pop up. Let's look at a few top stock trades as we kick off the week. Top Stock Trades for Tomorrow No. 1: Chewy (CHWY)Source: Chart courtesy of StockCharts.comChewy (NYSE:CHWY) is set to report earnings after the close Monday, as are our Top Trades No. 2 and 3.Over the last few trading sessions, CHWY stock has fought hard to break out over downtrend resistance (blue line). To its credit, Chewy stock has done a good job holding up over this mark, although it struggled in Monday's session.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAfter the company reports after the close, it's vital that the stock doesn't go on to make new lows below $21.68. If it does, it puts $20 -- and possibly the teens -- on the table. Ideally though, CHWY will hold up over the 20-day moving average at $23.57, as well as downtrend resistance. * 7 Overlooked Value Stocks to Buy That Will Shine in 2020 On the upside, let's see if CHWY can clear some of the clutter near current levels. Specifically, let's see if it can clear the 50-day moving average and the $25 level. Above that puts the 78.6% retracement just below $26 on the table. Moving above all of these levels puts the declining 100-day moving average near $28 on the table. Top Stock Trades for Tomorrow No. 2: Toll Brothers (TOL)Source: Chart courtesy of StockCharts.comI have routinely highlighted Toll Brothers (NYSE:TOL) as a relative strength leader. The stock has a pattern of ripping to new highs, consolidating its gains and rallying to new highs again.Can it do it again on earnings?TOL stock is trying to break out over the $41.50 level. See if it can get above and more importantly, stay above this level after its post-earnings reaction. If it can, a breakout maybe in the making.On a decline, see where support comes into play. Can TOL hold its 20-day and 50-day moving averages near $40? How about uptrend support (blue line) near $39.50? Falling below the pattern puts $38.50 on the table. Below that and the 200-day moving average is possible. Top Stock Trades for Tomorrow No. 3: Stitch Fix (SFIX)Source: Chart courtesy of StockCharts.comStitch Fix (NASDAQ:SFIX) shares made an impressive move Monday, breaking out over $24. Of course, the whole move could be for naught, depending on the post-earnings reaction.On a pullback, it would be ideal for SFIX stock to hold this $24 breakout level as support. But given SFIX's history of volatility, that's also unlikely. So on the downside, let's see if $22 can hold as support. There it has short-term uptrend support (blue line), as well as the 100-day moving average. Further, its 50-day moving average sits at $22.28. Below this area could put $18 on the table.On the upside, let's see if SFIX can reclaim its 50% retracement near $26.90. Above that puts the 61.8% retracement on the table. Top Stock Trades for Tomorrow No. 4: Bluebird bio (BLUE)Source: Chart courtesy of StockCharts.comIt has been a tough run for bluebird bio (NASDAQ:BLUE), as highlighted by Monday's 2.7% decline. In late November, BLUE broke out over downtrend resistance (blue line), but found $85 and the 50-day moving average to be resistance.After Monday's pullback, the backside of that downtrend mark buoyed the share price. For bulls, the setup is now simple.On the downside, prior downtrend resistance and the $72 level have to hold as support. On the upside, bulls need to reclaim $85 and the 50-day moving average. Top Stock Trades for Tomorrow No. 5: Shopify (SHOP)Source: Chart courtesy of StockCharts.comShopify (NASDAQ:SHOP) has been getting a lot of attention lately and deservedly so.Again, keep this one as simple as you can. Recent resistance has come into play at $375. Above it opens the door to $400. At the same time, recent support has come into play near $360. Below it puts $340 on the table. Below that and the 50-day moving average will be key.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks That Are Still Worth Buying In 2020 * 7 Strong Stocks to Buy That Won Q3 Earnings * 5 Safety Stocks to Buy Without Trade War Exposure The post 5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP appeared first on InvestorPlace.
Shares took off Monday morning after the company reported data at a medical conference over the weekend that relieved investor anxiety over the company’s experimental cancer drug ide-cel.